INFI - インフィニティ・ファ―マシュ―ティカルズ (Infinity Pharmaceuticals Inc.) インフィニティ・ファ―マシュ―ティカルズ

 INFIのチャート


 INFIの企業情報

symbol INFI
会社名 Infinity Pharmaceuticals Inc (インフィニティ・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 インフィニティ・ファーマシューティカルズ(Infinity Pharmaceuticals Inc.)は創薬・新薬開発会社。同社の主力製品は同社が血液悪性腫瘍と炎症性疾患において研究しているクラスI ・PI3K- デルタとPI3K- ガンマの強力な経口阻害剤である。同社のretaspimycin塩酸塩(HCl)は熱ショック蛋白質90(Hsp90)の強力な選択的阻害剤である。ホスホイノシチド3 - キナーゼ(PI3K)は中心ノードとして細胞表面受容体から下流の生化学的事象へ信号を伝達する重要な細胞信号伝達蛋白質である。同社のこのプログラムにおける主力開発候補は臨床試験が行われた、血液悪性腫瘍と炎症性疾患を形成するクラスI PI3K-デルタ・ガンマの強力な経口阻害剤IPI-145である。血液悪性腫瘍は血液・骨髄の癌であり、慢性リンパ性白血病(CLL)、ホジキンリンパ腫、非ホジキンリンパ腫(NHL)などの白血病とリンパ腫を含む。   インフィニティ・ファ―マシュ―ティカルズは、米国のバイオ医薬品企業。主力製品候補のIPI-145は血液悪性腫瘍と炎症性疾患を対象とする、ホスホイノシチド3-キナ―ゼ(PI3K)のクラスIデルタとガンマアイソフォ―ムの経口阻害剤である。またIPI-443などを参考に、第二のPI3K製品候補、PI3Kデルタとガンマの経口阻害剤を開発。   
本社所在地 784 Memorial Drive Cambridge MA 02139 USA
代表者氏名 Adelene Q. Perkins アデリーンQ.パーキンス
代表者役職名 Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者
電話番号 +1 617-453-1000
設立年月日 34759
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 22人
url www.infi.com
nasdaq_url https://www.nasdaq.com/symbol/infi
adr_tso
EBITDA EBITDA(百万ドル) -32.06800
終値(lastsale) 2.45
時価総額(marketcap) 139283842.6
時価総額 時価総額(百万ドル) 144.96890
売上高 売上高(百万ドル) 6.00000
企業価値(EV) 企業価値(EV)(百万ドル) 95.80390
当期純利益 当期純利益(百万ドル) 43.64100
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Infinity Pharmaceuticals Inc. revenues was not reported. Net loss decreased 40% to $16.4M. Lower net loss reflects Other expense decrease from $6.9M (expense) to $0K Other General and administrative decrease of 44% to $5.5M (expense) Stock Based compensation in General and decrease of 46% to $1.5M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.54 to -$0.31.

 INFIのテクニカル分析


 INFIのニュース

   Infinity Pharmaceuticals Must-See Earnings Estimates for: Stock market Insights & financial analysis  2021/03/02 09:46:00 Stock Market Daily
Infinity Pharmaceuticals announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Infinity Announces Closing of $92 Million Public Offering of Common Stock  2021/02/18 13:30:00 Business Wire
Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a potential
   Infinity Announces Pricing of $80 Million Public Offering of Common Stock  2021/02/12 13:30:00 Business Wire
Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a potential
   The Daily Biotech Pulse: European Regulatory Nod For Xeris, Amicus Falls On Data, 4 IPOs, FDA Decision For Mallinckrodt's StrataGraft Delayed  2021/02/12 13:10:51 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 12) 4D Molecular Therapeutics Inc (NASDAQ: FDMT ) Adagene Inc (NASDAQ: ADAG ) (went public Tuesday) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) AnaptysBio Inc (NASDAQ: ANAB ) (received a double upgrade from JPMorgan) AngioDynamics, Inc. (NASDAQ: ANGO ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) argenx SE – ADR (NASDAQ: ARGX ) Atea Pharmaceuticals Inc (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) Ayala Pharmaceuticals Inc (NASDAQ: AYLA ) Bausch Health Companies Inc (NYSE: BHC ) Bolt Biotherapeutics Inc (NASDAQ: BOLT ) C4 Therapeutics Inc (NASDAQ: CCCC ) Cara Therapeutics Inc (NASDAQ: CARA ) Celcuity Inc (NASDAQ: CELC ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Collplant Biotechnologies Ltd – ADR (NASDAQ: CLGN ) DermTech Inc (NASDAQ: DMTK ) ( announced award of contract for coverage of its skin cancer gene expression test) ESSA Pharma Inc (NASDAQ: EPIX ) (reacted to first-quarter results) Evogene Ltd (NASDAQ: EVGN ) FibroGen Inc (NASDAQ: FGEN ) G1 Therapeutics Inc (NASDAQ: GTHX ) Genetron Holdings Ltd – ADR (NASDAQ: GTH ) GenMark Diagnostics, Inc (NASDAQ: GNMK ) (moved on M&A speculation) Guardant Health Inc (NASDAQ: GH ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunome Inc (NASDAQ: IMNM ) Infinity Pharmaceuticals Inc.
   Infinity Pharmaceuticals Presents Data from Randomized, Placebo-Controlled, Phase 2 MARIO-275 Trial of Eganelisib and Nivolumab in Advanced Urothelial Cancer at ASCO Genitourinary Cancers Symposium  2021/02/11 12:15:00 Business Wire
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”) today presented data from MARIO-275 (MAcrophage Reprogramming in Immune On
   Infinity Announces Closing of $92 Million Public Offering of Common Stock  2021/02/18 13:30:00 Business Wire
Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a potential
   Infinity Announces Pricing of $80 Million Public Offering of Common Stock  2021/02/12 13:30:00 Business Wire
Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a potential
   The Daily Biotech Pulse: European Regulatory Nod For Xeris, Amicus Falls On Data, 4 IPOs, FDA Decision For Mallinckrodt's StrataGraft Delayed  2021/02/12 13:10:51 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 12) 4D Molecular Therapeutics Inc (NASDAQ: FDMT ) Adagene Inc (NASDAQ: ADAG ) (went public Tuesday) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) AnaptysBio Inc (NASDAQ: ANAB ) (received a double upgrade from JPMorgan) AngioDynamics, Inc. (NASDAQ: ANGO ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) argenx SE – ADR (NASDAQ: ARGX ) Atea Pharmaceuticals Inc (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) Ayala Pharmaceuticals Inc (NASDAQ: AYLA ) Bausch Health Companies Inc (NYSE: BHC ) Bolt Biotherapeutics Inc (NASDAQ: BOLT ) C4 Therapeutics Inc (NASDAQ: CCCC ) Cara Therapeutics Inc (NASDAQ: CARA ) Celcuity Inc (NASDAQ: CELC ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Collplant Biotechnologies Ltd – ADR (NASDAQ: CLGN ) DermTech Inc (NASDAQ: DMTK ) ( announced award of contract for coverage of its skin cancer gene expression test) ESSA Pharma Inc (NASDAQ: EPIX ) (reacted to first-quarter results) Evogene Ltd (NASDAQ: EVGN ) FibroGen Inc (NASDAQ: FGEN ) G1 Therapeutics Inc (NASDAQ: GTHX ) Genetron Holdings Ltd – ADR (NASDAQ: GTH ) GenMark Diagnostics, Inc (NASDAQ: GNMK ) (moved on M&A speculation) Guardant Health Inc (NASDAQ: GH ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunome Inc (NASDAQ: IMNM ) Infinity Pharmaceuticals Inc.
   Infinity Pharmaceuticals Presents Data from Randomized, Placebo-Controlled, Phase 2 MARIO-275 Trial of Eganelisib and Nivolumab in Advanced Urothelial Cancer at ASCO Genitourinary Cancers Symposium  2021/02/11 12:15:00 Business Wire
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”) today presented data from MARIO-275 (MAcrophage Reprogramming in Immune On
   Why Infinity Pharma, Meridian Bio, More Biotech Stocks Are Moving Today  2021/02/05 17:34:09 Benzinga
Infinity Pharmaceuticals (NASDAQ: INFI ) shares are trading higher Friday after JPMorgan upgraded the stock from Underweight to Neutral. Infinity Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel medicines for the treatment of specific cancers. Infinity has a strategic partnership with AbbVie to develop some of its oncology-related treatments. The company operates in only one segment: drug development. Infinity Pharmaceuticals shares were trading up 8.54% at $4. The stock has a 52-week high of $4.38 and a 52-week low of 60 cents. Orchard Therapeutics (NASDAQ: ORTX ) shares are trading higher after the company reported $150 million in strategic financing. Orchard Therapeutics is a United Kingdom-based, … Full story available on Benzinga.com
   Infinity Pharmaceuticals Presents Data from Randomized, Placebo-Controlled, Phase 2 MARIO-275 Trial of Eganelisib and Nivolumab in Advanced Urothelial Cancer at ASCO Genitourinary Cancers Symposium  2021/02/11 12:15:00 Business Wire
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”) today presented data from MARIO-275 (MAcrophage Reprogramming in Immune On
   Why Infinity Pharma, Meridian Bio, More Biotech Stocks Are Moving Today  2021/02/05 17:34:09 Benzinga
Infinity Pharmaceuticals (NASDAQ: INFI ) shares are trading higher Friday after JPMorgan upgraded the stock from Underweight to Neutral. Infinity Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel medicines for the treatment of specific cancers. Infinity has a strategic partnership with AbbVie to develop some of its oncology-related treatments. The company operates in only one segment: drug development. Infinity Pharmaceuticals shares were trading up 8.54% at $4. The stock has a 52-week high of $4.38 and a 52-week low of 60 cents. Orchard Therapeutics (NASDAQ: ORTX ) shares are trading higher after the company reported $150 million in strategic financing. Orchard Therapeutics is a United Kingdom-based, … Full story available on Benzinga.com
   Infinity Pharmaceuticals Announces MARIO-275 Phase 2 Data in Patients with Advanced Urothelial Cancer to be Presented at ASCO Genitourinary Cancers Symposium  2021/01/11 13:05:00 Yahoo Finance
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be presenting data from MARIO-275 on the first day of the American Society of Clinical Oncology (ASCO) 2021 Genitourinary Cancers Symposium to be held virtually, February 11-13, 2021. MARIO-275 is a randomized, placebo- controlled Phase 2 study evaluating the benefit of adding eganelisib to nivolumab (Opdivo®) in platinum-refractory, I/O naïve patients with advanced urothelial cancer over nivolumab monotherapy, which is approved in this setting.
   71 Biggest Movers From Yesterday  2020/12/09 10:02:01 Benzinga
Gainers Curis, Inc. (NASDAQ: CRIS ) stock climbed 354.9% to close at $6.55 on Tuesday after the company announced "positive" preliminary data from an ongoing Phase 1 study of CA-4948 monotherapy in patients with leukemia and myelodysplastic syndromes. Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) shares surged 78% to close at $3.08 after Citigroup upgraded the stock from Neutral to Buy and raised its price target from $2.1 to $6 per share. IGM Biosciences, Inc. (NASDAQ: IGMS ) gained 57.8% to close at $115.03. IGM Biosciences reported a $150 million common stock offering. Mammoth Energy Services, Inc. (NASDAQ: TUSK ) jumped 57.2% to close at $3.19 after the company said additional reports from FEMA 'add further validation' to work performed in Puerto Rico. Liquidity Services, Inc. (NASDAQ: LQDT ) jumped 41.5% to close at $14.90 after the company reported upbeat Q4 results. Stitch Fix, Inc. (NASDAQ: SFIX ) shares gained 39.2% to close at $49.89 after the company reported stronger-than-expected Q1 result.
   The Daily Biotech Pulse: Lilly Secures Additional Orders For COVID-19 Antibody Treatment, Decision Day For BioCryst, Kinnate Biopharma To Make Wall Street Debut  2020/12/03 12:46:12 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 2) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Beam Therapeutics Inc (NASDAQ: BEAM ) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Cerevel Therapeutics Holdings Inc (NASDAQ: CERE ) Fate Therapeutics Inc (NASDAQ: FATE ) Generation Bio Co (NASDAQ: GBIO ) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Infinity Pharmaceuticals Inc. (NASDAQ: INFI ) Inhibrx Inc (NASDAQ: INBX ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Iovance Biotherapeutics Inc (NASDAQ: IOVA ) Inspire Medical Systems Inc (NYSE: INSP ) Kymera Therapeutics Inc (NASDAQ: KYMR ) Larimar Therapeutics Inc (NASDAQ: LRMR ) Merrimack Pharmaceuticals Inc (NASDAQ: MACK ) (reacted to positive outlook for the cancer drug it sold to Ispen, which opens the possibility of realizing potential milestone payments) Myovant Sciences Ltd (NYSE: MYOV ) Ocular Therapeutix Inc (NASDAQ: OCUL ) Olema Pharmaceuticals Inc (NASDAQ: OLMA ) Oncorus Inc (NASDAQ: ONCR ) OncoSec Medical Inc (NASDAQ: ONCS ) Pfizer Inc. (NYSE: PFE ) ( announced U.K. regulatory nod for emergency use of its coronavirus vaccine candidate) Praxis Precision Medicines Inc (NASDAQ: PRAX ) Pulse Biosciences Inc (NASDAQ: PLSE ) Spero Therapeutics Inc (NASDAQ: SPRO ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Dec. 2) Histogen Inc (NASDAQ: HSTO ) Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV ) (shares will trade …

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 インフィニティ・ファ―マシュ―ティカルズ INFI Infinity Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)